Research shows that dantrolene, a drug that controls calcium levels inside cells, significantly reduced liver scarring and prevented precancerous changes in rats with MASH (a serious fatty liver disease). According to Gram Research analysis of this 2026 study, dantrolene worked by stopping the calcium imbalances that trigger liver damage and scarring. While these results are promising, the drug has only been tested in animals and human cells so far, not in people, so it’s not yet available as a treatment.
Researchers discovered that a drug called dantrolene may help treat a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis), which causes fat buildup, inflammation, and scarring in the liver. According to Gram Research analysis, the study found that dantrolene works by fixing a calcium imbalance inside liver cells that contributes to the disease. When tested in rats with MASH, the drug reduced liver scarring and prevented precancerous changes. The findings suggest that controlling calcium levels in liver cells could be a new way to treat this disease, which currently has few effective medications.
Key Statistics
A 2026 research article found that dantrolene treatment markedly reduced liver fibrosis (scarring) and significantly decreased precancerous lesions in rats with MASH, a progressive fatty liver disease.
According to a 2026 study published in Biochemical and Biophysical Research Communications, dantrolene suppressed calcium dysregulation in human liver cells, preventing the cellular activation that leads to liver scarring.
Research reviewed by Gram showed that dantrolene partially improved blood markers of liver cell injury in MASH rats, though it did not reduce overall liver enlargement.
The Quick Take
- What they studied: Whether a drug called dantrolene can reduce liver damage and scarring in a disease called MASH by fixing calcium imbalances inside liver cells
- Who participated: Rats with MASH (a fatty liver disease similar to what humans get), plus human liver cells grown in the laboratory
- Key finding: Dantrolene significantly reduced liver scarring and prevented precancerous changes in rats with MASH, and it stopped calcium buildup in human liver cells that normally causes damage
- What it means for you: This research suggests a potential new treatment approach for fatty liver disease, though human testing is still needed before it could be used as a medicine. People with MASH should continue following their doctor’s current recommendations while researchers work on developing this treatment further.
The Research Details
Scientists used rats that were fed a special diet to develop MASH (a disease where fat builds up in the liver, causing inflammation and scarring). They gave some rats dantrolene, a drug that blocks calcium channels in cells, and compared them to rats that didn’t receive the drug. The researchers examined the rats’ livers under a microscope and measured chemicals in their blood that indicate liver damage. They also studied how dantrolene affected human liver cells in dishes to understand exactly how the drug works at the cellular level.
The researchers focused on calcium because previous studies suggested that when calcium levels get out of control inside liver cells, it triggers a chain reaction that damages the liver and causes scarring. By using dantrolene to control calcium, they wanted to see if they could stop this damage before it happened.
This research approach is important because it identifies a specific problem (calcium imbalance) and tests a drug that targets that exact problem. Most current MASH treatments don’t work very well, so finding a new target could lead to better medications. Testing in both animals and human cells helps researchers understand whether the drug actually works and how it works before trying it in people.
The study used a well-established rat model of MASH that closely mimics the human disease, which is a strength. The researchers examined multiple markers of liver damage and used advanced imaging to see calcium changes in real time. However, because this is an animal study, results may not translate exactly to humans. The study was published in a peer-reviewed scientific journal, meaning other experts reviewed the work before publication. The sample size of rats was not specified in the abstract, which limits our ability to assess statistical power.
What the Results Show
Dantrolene treatment significantly reduced liver scarring (fibrosis) in rats with MASH, which is the most important finding because scarring is what makes the disease dangerous and hard to treat. The drug also prevented precancerous changes in liver tissue, suggesting it might reduce cancer risk. When researchers looked at liver cells under the microscope, they saw much less scarring tissue in the dantrolene-treated rats compared to untreated rats.
At the cellular level, dantrolene stopped fat from building up inside liver cells when they were exposed to free fatty acids. In human liver cells grown in dishes, the drug blocked the activation of stellate cells—special cells that cause scarring when they become activated. The drug worked by reducing the abnormal calcium spikes that normally trigger this scarring process.
Dantrolene partially improved blood markers of liver damage, though it didn’t completely normalize them. The drug did not reduce liver enlargement, suggesting it works specifically on scarring and inflammation rather than on all aspects of the disease. These findings indicate that while dantrolene is effective at preventing scarring, it may need to be combined with other treatments to address all aspects of MASH.
Previous research suggested that calcium imbalances contribute to liver disease, but this is one of the first studies to show that blocking calcium channels with dantrolene can actually reduce scarring in MASH. Most current MASH treatments focus on weight loss or managing diabetes, rather than targeting the cellular mechanisms of scarring. This research opens a new avenue by targeting calcium signaling, which hasn’t been a major focus of MASH drug development until now.
This study was conducted in rats and human cells in dishes, not in living humans, so results may not translate directly to people. The exact dose and duration of treatment that would work best in humans is unknown. The study doesn’t tell us whether dantrolene would work in people who already have advanced scarring, or only in early stages. Long-term safety of dantrolene in MASH patients hasn’t been tested. The study also didn’t compare dantrolene to other potential treatments, so we don’t know if it’s better or worse than other approaches.
The Bottom Line
Based on this research, dantrolene is a promising candidate for future MASH treatment, but it is not yet ready for human use. People with MASH should continue following their doctor’s current recommendations, which typically include weight loss, managing blood sugar, and treating related conditions like high cholesterol. This research suggests that within the next 5-10 years, calcium-targeting drugs like dantrolene could become part of the treatment toolkit for MASH.
This research is most relevant to people with MASH (fatty liver disease with inflammation and scarring), people at risk for MASH (those with obesity, type 2 diabetes, or metabolic syndrome), and their doctors. Researchers and pharmaceutical companies developing new MASH treatments should pay close attention to these findings. People without liver disease don’t need to take action based on this research yet.
If dantrolene moves forward to human testing, it would typically take 5-10 years before it could become an approved medication. Early human trials would need to confirm that the drug is safe and works in people the way it worked in rats. Even if approved, benefits would likely develop gradually over weeks to months of treatment, similar to other liver disease medications.
Frequently Asked Questions
What is MASH and why is it dangerous?
MASH is a liver disease where fat builds up in liver cells, causing inflammation and scarring. It’s dangerous because scarring (fibrosis) can eventually lead to liver failure and cancer. Currently, few effective medications exist to stop the scarring process.
How does dantrolene treat fatty liver disease?
Dantrolene works by controlling calcium levels inside liver cells. When calcium gets out of balance, it triggers cells called stellate cells to activate and create scar tissue. By fixing the calcium imbalance, dantrolene stops this scarring process before it starts.
When will dantrolene be available as a treatment for MASH?
Dantrolene is not yet available for MASH treatment. This study was in animals and cells only. If development continues, human clinical trials would typically take 5-10 years before the drug could potentially be approved for patient use.
Can I take dantrolene now if I have fatty liver disease?
No, dantrolene is not approved for MASH treatment and should not be used for this purpose without a doctor’s guidance. Continue following your doctor’s current recommendations for managing fatty liver disease while researchers develop new treatments.
What should I do right now if I have MASH?
Work with your doctor on proven strategies: lose weight if overweight, manage blood sugar and cholesterol, limit alcohol, and eat a healthy diet. Regular monitoring with blood tests and ultrasound helps track disease progression. Ask your doctor about clinical trials testing new MASH treatments.
Want to Apply This Research?
- Track liver health markers monthly: record any blood test results showing liver enzyme levels (ALT, AST) and fibrosis scores if available from your doctor. Note any changes in energy levels, abdominal bloating, or digestive symptoms that might indicate liver improvement.
- Use the app to log daily habits that protect liver health while waiting for new treatments: record alcohol consumption (aim for zero), track meals to monitor fat and sugar intake, log exercise minutes, and monitor weight changes. Set reminders for doctor appointments to check liver function tests.
- Create a 6-month tracking dashboard showing trends in liver enzyme levels, weight, and lifestyle factors. Share this data with your doctor at each visit to assess whether current treatments are working and to discuss when new options like dantrolene might become available for human use.
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. MASH is a serious medical condition that requires professional diagnosis and treatment. Do not start, stop, or change any medications without consulting your healthcare provider. Dantrolene is not currently approved for MASH treatment. If you have fatty liver disease or suspect you might, speak with your doctor about appropriate screening, monitoring, and treatment options. This research represents early-stage findings in animals and laboratory cells; human safety and efficacy have not been established.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.